

Supplementary Table 5. Age and Sex Distribution of UC Patients Registered in the MDV Database and Those Registered in the Japan Intractable Diseases System

	Patients who were diagnosed with UC in the MDV claims database					UC patients registered in the Japan Intractable Diseases System ^a				
	FY2018 (n = 48,978)	FY2019 (n = 53,028)	FY2020 (n = 55,600)	FY2021 (n = 57,029)	FY2022 (n = 56,769)	FY2018 ^b (n = 124,961)	FY2019 ^b (n = 126,603)	FY2020 ^b (n = 140,574)	FY2021 ^b (n = 138,079)	FY2022 ^b (n = 141,387)
Age (yr)										
< 10	67 (0.1)	80 (0.2)	76 (0.1)	116 (0.2)	132 (0.2)	9 (0.0)	5 (0.0)	5 (0.0)	3 (0.0)	4 (0.0)
10 to <20	1,302 (2.7)	1,415 (2.7)	1,519 (2.7)	1,604 (2.8)	1,587 (2.8)	1,416 (1.1)	1,339 (1.1)	1,331 (0.9)	1,175 (0.9)	1,150 (0.8)
20 to <30	4,386 (9.0)	4,804 (9.1)	4,838 (8.7)	4,983 (8.7)	4,791 (8.4)	12,784 (10.2)	13,133 (10.4)	15,204 (10.8)	14,646 (10.6)	15,089 (10.7)
30 to <40	6,929 (14.1)	7,284 (13.7)	7,437 (13.4)	7,366 (12.9)	7,033 (12.4)	20,340 (16.3)	20,399 (16.1)	22,740 (16.2)	21,780 (15.8)	21,816 (15.4)
40 to <50	10,218 (20.9)	10,655 (20.1)	10,788 (19.4)	10,754 (18.9)	10,395 (18.3)	29,347 (23.5)	29,216 (23.1)	31,697 (22.5)	30,456 (22.1)	30,396 (21.5)
50 to <60	8,737 (17.8)	9,713 (18.3)	10,498 (18.9)	10,994 (19.3)	11,185 (19.7)	24,169 (19.3)	25,246 (19.9)	28,371 (20.2)	28,869 (20.9)	30,318 (21.4)
60 to <70	7,811 (15.9)	8,299 (15.7)	8,618 (15.5)	8,844 (15.5)	8,977 (15.8)	19,321 (15.5)	19,076 (15.1)	20,574 (14.6)	20,542 (14.9)	21,285 (15.1)
70 to <75	3,591 (7.3)	4,146 (7.8)	4,732 (8.5)	5,025 (8.8)	4,775 (8.4)	7,952 (6.4)	8,364 (6.6)	9,760 (6.9)	9,768 (7.1)	9,610 (6.8)
≥ 75	5,937 (12.1)	6,632 (12.5)	7,094 (12.8)	7,343 (12.9)	7,894 (13.9)	9,623 (7.7)	9,825 (7.8)	10,892 (7.7)	10,840 (7.9)	11,719 (8.3)
Sex										
Male	26,939 (55.0)	29,204 (55.1)	30,821 (55.4)	31,755 (55.7)	31,758 (55.9)					
Female	22,039 (45.0)	23,824 (44.9)	24,779 (44.6)	25,274 (44.3)	25,011 (44.1)					
Ratio	1.2:1	1.2:1	1.2:1	1.3:1	1.3:1					

Values are presented as number (%) unless otherwise indicated.

^aPatients receiving UC treatment subsidies from the Japan Intractable Diseases System established by the Ministry of Health, Labour and Welfare for patients with intractable diseases, including UC in Japan. In Japan, UC patients must be registered in this system annually to receive medical expense subsidies. The system covers approximately 70% of UC patients nationwide.

^bReport on Public Health Administration and Services [in Japanese]. Japanese Ministry of Health Labour and Welfare, 2018–2022. https://www.nanbyou.or.jp/wp-content/uploads/upload_files/koufu20191.xlsx, <https://www.nanbyou.or.jp/wp-content/uploads/2021/03/koufu20201.xlsx>, <https://www.nanbyou.or.jp/wp-content/uploads/2022/03/koufu20211.xlsx>, <https://www.nanbyou.or.jp/wp-content/uploads/2023/02/koufu20221.xlsx>, <https://www.nanbyou.or.jp/wp-content/uploads/2024/01/koufu20231.xlsx>. Accessed December 17, 2024.

UC, ulcerative colitis; MDV, Medical Data Vision; FY, financial year.